厄洛替尼治疗晚期非小细胞肺癌的临床研究

目的观察厄洛替尼治疗晚期非小细胞肺癌的疗效及不良反应。方法纳入34例经病理学诊断的晚期（ⅢA期或Ⅳ期）非小细胞肺癌患者，口服厄洛替尼150mg每天1次，并采用Fisher确切概率法行疗效评价。结果34例患者中．CR1例，PR16例，SD8例，PD9饲；其中性别、病理类型、吸烟史和PS评分均与RR、DCR无显著相关性，既往化疗方案数与DCR有相关性。生存期随访至2008年7月，全组中住生存时间6．7个月（2．5～14个月），中位疾病进展时间5个月（1～14个月），1年生存率34．5％。不良反应以皮疹、腹泻、白细胞下降和转氨酶升高为主，多为轻度。结论厄洛替尼治疗晚期非小细胞肺癌有较好的安全性和有效性；不同性别、病理类型、吸烟史和PS评分的患者其疗效没有显著差别。既往化疗方案个数≤1个者疾病控制率高于≥2个者。

The clinical observation of erlotinib in advanced stage nsclc

Objective To observe the curative and side effect of advanced stage non-small cell lung cancer treated with erlotinib. Methods 34 patients with advanced stage NSCLC（ Ⅲ A or Ⅳ） were confirmed with pathology. The patients were orally administrated with erlotinib. The anticancer effects were analyzed by Fisher＇s exact probabilities test. Results Patients at CR, PR, SD and PD were 1, 16, 8 and 9 cases, respectively. Gender, pathology type, history of smoking and PS were not related to RR. The median survival time was 6.7 months （2.5-14 months）. The median time of progression was 5 months （1-14 months）. 1 year survival rate was 34.5%. The most common adverse events were rash, diarrhea, descending of WBC and ascending of aminoferase. Most of them were moderately benign. Conclusion It seems safe and effective to treating advanced stage NSCLC with erlotinib. There were no predominantly differences between gender, pathology types, history of smoking and PS.